Selected problems in immunosuppressive therapy.
D000477:Alkylating Agents / Q000009:adverse effects / Q000627:therapeutic use; D000818:Animals; D000917:Antibody Formation; D000963:Antimetabolites / Q000009:adverse effects / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000188:drug therapy; D002277:Carcinoma / Q000139:chemically induced; D002455:Cell Division / Q000187:drug effects; D006801:Humans; D007109:Immunity; D007111:Immunity, Cellular; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D007239:Infections / Q000276:immunology; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy / Q000276:immunology; D008222:Lymphokines; D016403:Lymphoma, Large B-Cell, Diffuse / Q000139:chemically induced; D015122:Mercaptopurine / Q000009:adverse effects / Q000627:therapeutic use; D009154:Mutation / Q000187:drug effects; D009369:Neoplasms / Q000139:chemically induced
D000477:Alkylating Agents; D000963:Antimetabolites; D007166:Immunosuppressive Agents; D008222:Lymphokines; D015122:Mercaptopurine